High resting triacylglycerol turnover of rainbow trout exceeds the energy requirements of endurance swimming.
Fish may use lipoproteins instead of albumin-bound fatty acids to fuel endurance exercise, but lipoprotein kinetics have never been measured in ectotherms. In vivo bolus injections of labeled very-low-density lipoproteins ((3)H-VLDL labeled in vivo from donor fish) and continuous infusions of Intralipid (3H-labeled artificial emulsion) were used to investigate the effects of prolonged exercise (6 h at 1.5 body length/s) and heparin (600 U/kg) on the turnover rate of circulating triacylglycerol (TAG) in rainbow trout. We hypothesized that swimming would stimulate TAG turnover rate to fuel working muscles and that heparin would reduce flux by releasing lipoprotein lipase (LPL) from endothelial cells. Results from both tracer methods show that the baseline TAG turnover rate of trout ranges from 24 to 49 mumol TAG.kg(-1) x min(-1) and exceeds all values measured to date in endotherms. More important, this high resting turnover rate is not stimulated during swimming, because it can already cover several times the energy requirements of locomotion. The fact that heparin causes a 50% decrease in baseline TAG turnover rate suggests that fish LPL must be bound to the endothelium for normal tissue uptake of fatty acids supplied by lipoproteins, as in mammals. We propose that the high resting TAG turnover rate of rainbow trout could be needed by ectotherms for rapid restructuring of membrane phospholipids. The continuous tracer infusion method implemented here could be a versatile tool to investigate the potential role of lipoproteins in providing fatty acids for rapid homeoviscous adaptation.
Magnoni
Leonardo
L
Biology Department, University of Ottawa, Ottawa, Ontario, Canada.
Vaillancourt
Eric
E
Weber
Jean-Michel
JM
D000818:Animals; D004734:Energy Metabolism / Q000502:physiology*; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006493:Heparin / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D017686:Oncorhynchus mykiss / Q000378:metabolism*; D010805:Physical Conditioning, Animal / Q000502:physiology*; D010807:Physical Endurance / Q000502:physiology*; D013550:Swimming / Q000502:physiology; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism* / Q000493:pharmacokinetics
D005217:Fat Emulsions, Intravenous; D014280:Triglycerides; D006493:Heparin